BioCentury
ARTICLE | Company News

Hubei Qianjiang, TNI BioTech deal

October 29, 2012 7:00 AM UTC

TNI and Hubei partnered to co-develop TNI's cancer therapeutic candidates IRT-101 and IRT-102 in China. Hubei will fund all clinical development and has committed an additional RMB10 million ($1.6 million) to fund preclinical trials. In exchange, Hubei will have rights to commercialize the products in China. TNI will ensure preclinical and clinical trials comply with both FDA and China's State Food and Drug Administration (SFDA) regulations. According to TNI, the next steps in development of both compounds in China are contingent on whether or not SFDA will require an additional large animal trial. IRT-101 completed Phase II testing in the U.S. to treat cancer. ...